

Richard T Eastman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8894957/publications.pdf>

Version: 2024-02-01

44
papers

3,638
citations

201674

27
h-index

233421

45
g-index

54
all docs

54
docs citations

54
times ranked

5810
citing authors

#	ARTICLE	IF	CITATIONS
1	Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Science, 2020, 6, 672-683.	11.3	684
2	Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nature Reviews Microbiology, 2009, 7, 864-874.	28.6	440
3	Quantitative assessment of <i>Plasmodium falciparum</i> sexual development reveals potent transmission-blocking activity by methylene blue. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1214-23.	7.1	293
4	Drug-resistant malaria: Molecular mechanisms and implications for public health. FEBS Letters, 2011, 585, 1551-1562.	2.8	222
5	Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Molecular and Biochemical Parasitology, 2003, 126, 155-163.	1.1	126
6	Supragenomic Network Compression and the Discovery of EXP1 as a Glutathione Transferase Inhibited by Artesunate. Cell, 2014, 158, 916-928.	28.9	113
7	Thematic review series: Lipid Posttranslational Modifications. Fighting parasitic disease by blocking protein farnesylation. Journal of Lipid Research, 2006, 47, 233-240.	4.2	104
8	Piperaquine Resistance Is Associated with a Copy Number Variation on Chromosome 5 in Drug-Pressured <i>Plasmodium falciparum</i> Parasites. Antimicrobial Agents and Chemotherapy, 2011, 55, 3908-3916.	3.2	102
9	High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. Scientific Reports, 2015, 5, 13891.	3.3	92
10	Deep learning identifies synergistic drug combinations for treating COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	87
11	A Specific Inhibitor of PfCDPK4 Blocks Malaria Transmission: Chemical-genetic Validation. Journal of Infectious Diseases, 2014, 209, 275-284.	4.0	83
12	Recent highlights in antimalarial drug resistance and chemotherapy research. Trends in Parasitology, 2008, 24, 537-544.	3.3	80
13	Synergistic and Antagonistic Drug Combinations against SARS-CoV-2. Molecular Therapy, 2021, 29, 873-885.	8.2	78
14	Trypanosoma cruzi Inactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen) Tj ETQq0 0,0 rgBT /Overlock 10	3.2	77
15	Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. Frontiers in Pharmacology, 2020, 11, 592737.	3.5	69
16	Resistance to a Protein Farnesyltransferase Inhibitor in Plasmodium falciparum. Journal of Biological Chemistry, 2005, 280, 13554-13559.	3.4	66
17	Targeting ACE2-RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay. ACS Pharmacology and Translational Science, 2020, 3, 1352-1360.	4.9	60
18	The Candida albicans Lanosterol 14- α -Demethylase (ERG11) Gene Promoter Is Maximally Induced after Prolonged Growth with Antifungal Drugs. Antimicrobial Agents and Chemotherapy, 2004, 48, 1136-1144.	3.2	56

#	ARTICLE	IF	CITATIONS
19	Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from <i>Trypanosoma cruzi</i> and <i>Leishmania major</i> . <i>Molecular and Biochemical Parasitology</i> , 2002, 122, 181-188.	1.1	53
20	Design and Synthesis of Peptidomimetic Protein Farnesyltransferase Inhibitors as Anti- <i>Trypanosoma brucei</i> Agents. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 432-445.	6.4	49
21	Genome-wide profiling of chromosome interactions in <i>Plasmodium falciparum</i> characterizes nuclear architecture and reconfigurations associated with antigenic variation. <i>Molecular Microbiology</i> , 2013, 90, 519-537.	2.5	48
22	Artemisinin resistance phenotypes and K13 inheritance in a <i>Plasmodium falciparum</i> cross and <i>Aotus</i> model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12513-12518.	7.1	46
23	<i>Plasmodium vivax</i> chloroquine resistance links to pvcrt transcription in a genetic cross. <i>Nature Communications</i> , 2019, 10, 4300.	12.8	35
24	Ex Vivo Susceptibility of <i>Plasmodium falciparum</i> to Antimalarial Drugs in Western, Northern, and Eastern Cambodia, 2011-2012: Association with Molecular Markers. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5277-5283.	3.2	34
25	Oxidosqualene Cyclase Inhibitors as Antimicrobial Agents. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 4240-4243.	6.4	33
26	Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 791-7.	2.3	33
27	A Class of Tricyclic Compounds Blocking Malaria Parasite Oocyst Development and Transmission. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 425-435.	3.2	32
28	Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space. <i>ACS Central Science</i> , 2018, 4, 1727-1741.	11.3	32
29	Actinoramide A Identified as a Potent Antimalarial from Titration-Based Screening of Marine Natural Product Extracts. <i>Journal of Natural Products</i> , 2015, 78, 2411-2422.	3.0	30
30	Resistance mutations at the lipid substrate binding site of <i>Plasmodium falciparum</i> protein farnesyltransferase. <i>Molecular and Biochemical Parasitology</i> , 2007, 152, 66-71.	1.1	28
31	Using Machine Learning to Predict Synergistic Antimalarial Compound Combinations With Novel Structures. <i>Frontiers in Pharmacology</i> , 2018, 9, 1096.	3.5	27
32	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 31365-31375.	7.1	27
33	C-terminal proteolysis of prenylated proteins in trypanosomatids and RNA interference of enzymes required for the post-translational processing pathway of farnesylated proteins. <i>Molecular and Biochemical Parasitology</i> , 2007, 153, 115-124.	1.1	25
34	New WS9326A Derivatives and One New Annimycin Derivative with Antimalarial Activity are Produced by <i>Streptomyces asterosporus</i> DSM 41452 and Its Mutant. <i>ChemBioChem</i> , 2018, 19, 272-279.	2.6	25
35	A systematic and prospectively validated approach for identifying synergistic drug combinations against malaria. <i>Malaria Journal</i> , 2018, 17, 160.	2.3	19
36	Cloning and analysis of <i>Trypanosoma cruzi</i> lanosterol 14 α -demethylase. <i>Molecular and Biochemical Parasitology</i> , 2003, 132, 75-81.	1.1	18

#	ARTICLE	IF	CITATIONS
37	PfCRT and PfMDR1 modulate interactions of artemisinin derivatives and ion channel blockers. <i>Scientific Reports</i> , 2016, 6, 25379.	3.3	15
38	Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 40, 127906.	2.2	15
39	Regulation of <i>Plasmodium yoelii</i> Oocyst Development by Strain- and Stage-Specific Small-Subunit rRNA. <i>MBio</i> , 2015, 6, e00117.	4.1	11
40	Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite <i>Plasmodium falciparum</i> and Optimization Efforts. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2291-2309.	6.4	11
41	Modulation of Triple Artemisinin-Based Combination Therapy Pharmacodynamics by <i>Plasmodium falciparum</i> Genotype. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1144-1157.	4.9	8
42	A platform of assays for the discovery of anti-Zika small-molecules with activity in a 3D-bioprinted outer-blood-retina model. <i>PLoS ONE</i> , 2022, 17, e0261821.	2.5	6
43	Allosteric Binders of ACE2 Are Promising Anti-SARS-CoV-2 Agents. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 468-478.	4.9	3
44	Sulfamethoxazole Levels in HIV-Exposed Uninfected Ugandan Children. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 1718-1721.	1.4	1